174 related articles for article (PubMed ID: 38563850)
1. Repurposing mebendazole against triple-negative breast cancer CNS metastasis.
Rodrigues AJ; Chernikova SB; Wang Y; Trinh TTH; Solow-Cordero DE; Alexandrova L; Casey KM; Alli E; Aggarwal A; Quill T; Koegel AK; Feldman BJ; Ford JM; Hayden-Gephart M
J Neurooncol; 2024 May; 168(1):125-138. PubMed ID: 38563850
[TBL] [Abstract][Full Text] [Related]
2. Repurposing mebendazole against triple-negative breast cancer leptomeningeal disease.
Rodrigues A; Chernikova SB; Wang Y; Trinh TTH; Solow-Cordero DE; Alexandrova L; Casey KM; Alli E; Aggarwal A; Quill T; Koegel A; Feldman BJ; Ford JM; Hayden-Gephart M
Res Sq; 2024 Feb; ():. PubMed ID: 38405839
[TBL] [Abstract][Full Text] [Related]
3. Mebendazole Potentiates Radiation Therapy in Triple-Negative Breast Cancer.
Zhang L; Bochkur Dratver M; Yazal T; Dong K; Nguyen A; Yu G; Dao A; Bochkur Dratver M; Duhachek-Muggy S; Bhat K; Alli C; Pajonk F; Vlashi E
Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):195-207. PubMed ID: 30196056
[TBL] [Abstract][Full Text] [Related]
4. Anticancer Effect of Benzimidazole Derivatives, Especially Mebendazole, on Triple-Negative Breast Cancer (TNBC) and Radiotherapy-Resistant TNBC In Vivo and In Vitro.
Choi HS; Ko YS; Jin H; Kang KM; Ha IB; Jeong H; Song HN; Kim HJ; Jeong BK
Molecules; 2021 Aug; 26(17):. PubMed ID: 34500557
[TBL] [Abstract][Full Text] [Related]
5. Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways.
Huang L; Zhao L; Zhang J; He F; Wang H; Liu Q; Shi D; Ni N; Wagstaff W; Chen C; Reid RR; Haydon RC; Luu HH; Shen L; He TC; Tang L
Aging (Albany NY); 2021 Jul; 13(13):17407-17427. PubMed ID: 34232919
[TBL] [Abstract][Full Text] [Related]
6. Mebendazole prevents distant organ metastases in part by decreasing ITGβ4 expression and cancer stemness.
Joe NS; Godet I; Milki N; Ain NUI; Oza HH; Riggins GJ; Gilkes DM
Breast Cancer Res; 2022 Dec; 24(1):98. PubMed ID: 36578038
[TBL] [Abstract][Full Text] [Related]
7. Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC).
Zhang F; Li Y; Zhang H; Huang E; Gao L; Luo W; Wei Q; Fan J; Song D; Liao J; Zou Y; Liu F; Liu J; Huang J; Guo D; Ma C; Hu X; Li L; Qu X; Chen L; Yu X; Zhang Z; Wu T; Luu HH; Haydon RC; Song J; He TC; Ji P
Oncotarget; 2017 Feb; 8(8):12968-12982. PubMed ID: 28099902
[TBL] [Abstract][Full Text] [Related]
8. A Novel Brain-Permeant Chemotherapeutic Agent for the Treatment of Brain Metastasis in Triple-Negative Breast Cancer.
Deng J; Chernikova SB; Wang Y; Rodriguez ML; Andersen SJ; Umeh-Garcia MC; Godfrey BO; Ahmadian SS; Fischer WN; Koller KJ; Jandeleit B; Ringold GM; Gephart MH
Mol Cancer Ther; 2021 Nov; 20(11):2110-2116. PubMed ID: 34635566
[TBL] [Abstract][Full Text] [Related]
9. Mebendazole Increases Anticancer Activity of Radiotherapy in Radiotherapy-Resistant Triple-Negative Breast Cancer Cells by Enhancing Natural Killer Cell-Mediated Cytotoxicity.
Choi HS; Ko YS; Jin H; Kang KM; Ha IB; Jeong H; Lee JH; Jeong BK; Kim HJ
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555137
[TBL] [Abstract][Full Text] [Related]
10. Biodegradable and biocompatible subcutaneous implants consisted of pH-sensitive mebendazole-loaded/folic acid-targeted chitosan nanoparticles for murine triple-negative breast cancer treatment.
Kefayat A; Hosseini M; Ghahremani F; Jolfaie NA; Rafienia M
J Nanobiotechnology; 2022 Mar; 20(1):169. PubMed ID: 35361226
[TBL] [Abstract][Full Text] [Related]
11. Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer.
Zhen Y; Zhao R; Wang M; Jiang X; Gao F; Fu L; Zhang L; Zhou XL
Theranostics; 2020; 10(18):8080-8097. PubMed ID: 32724459
[No Abstract] [Full Text] [Related]
12. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
Jin K; Pandey NB; Popel AS
Breast Cancer Res; 2018 Jun; 20(1):54. PubMed ID: 29898755
[TBL] [Abstract][Full Text] [Related]
13. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract][Full Text] [Related]
14. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway.
Wu C; Qiu S; Liu P; Ge Y; Gao X
J Ethnopharmacol; 2018 Jan; 211():89-100. PubMed ID: 28962890
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo anticancer activity of mebendazole in colon cancer: a promising drug repositioning.
Aliabadi A; Haghshenas MR; Kiani R; Koohi-Hosseinabadi O; Purkhosrow A; Pirsalami F; Panjehshahin MR; Erfani N
Naunyn Schmiedebergs Arch Pharmacol; 2024 Apr; 397(4):2379-2388. PubMed ID: 37837472
[TBL] [Abstract][Full Text] [Related]
16. Mebendazole exhibits potent anti-leukemia activity on acute myeloid leukemia.
He L; Shi L; Du Z; Huang H; Gong R; Ma L; Chen L; Gao S; Lyu J; Gu H
Exp Cell Res; 2018 Aug; 369(1):61-68. PubMed ID: 29750898
[TBL] [Abstract][Full Text] [Related]
17. Tryptophan hydroxylase 1 and 5-HT
Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
[TBL] [Abstract][Full Text] [Related]
19. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
Xu S; Sun X; Luo L; Yang Y; Guo Q; Tang S; Jiang Z; Li Y; Han J; Gan W; Yang F; Zhang X; Liu Y; Sun C; He J; Liu M; Zuo D; Zhu W; Wu Y
Biomed Pharmacother; 2022 Nov; 155():113537. PubMed ID: 36113258
[TBL] [Abstract][Full Text] [Related]
20. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
